Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 12 week pilot and feasibility study with an enrollment goal of 30 subjects. Half of the subjects will be randomized to vitamin D3 and the other half will receive a placebo. Subjects will be referred from the nutrition or renal clinic at Emory. CKD stage 3 and 4 patients will be eligible for participation if they have been determined to have vitamin D deficiency and are not on treatment with vitamin D or vitamin D analogues. Subjects will sign an informed consent form after reviewing the protocol in detail with the principal investigator. A questionnaire would collect information about dietary vitamin D intake, sunlight exposure, and any symptoms of vitamin D deficiency. The subject will have baseline levels of serum vitamin D (25-hydroxyvitamin D), parathyroid hormone (PTH), serum calcium and phosphate, creatinine and other markers of bone turnover. The questionnaires and the blood draws would be repeated on the 6th and 12th week of the study. Subjects will be given 12 pills of each containing either 50,000 IU vitamin D or placebo and asked to take one pill a week. They would be scheduled to return to the clinic after 6 weeks and blood measurements would be repeated. Subjects will be asked to revisit for their final visit at the 12th week when they would have their last blood draw and assessment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D and Chronic Renal Insufficiency

NCT00968877

Vitamin D Deficiency Chronic Renal Insufficiency

COMPLETED PHASE3

Vitamin D Metabolism in Chronic Kidney Disease Patients

NCT01528176

Vitamin D Metabolism is in Chronic Kidney Disease

UNKNOWN NA

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

NCT00552409

Diabetes Mellitus Chronic Kidney Disease Diabetic Kidney Disease

COMPLETED PHASE2/PHASE3

The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease

NCT01029002

Chronic Renal Insufficiency Proteinuria

COMPLETED PHASE3

Vitamin D3 Supplementation in Dialysis Patients

NCT01312714

End-Stage Renal Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vitamin D supplementation in reducing secondary hyperparathyroidism in chronic kidney disease patients, stage 3 and 4: A randomized, placebo controlled pilot study Problem of interest Chronic Kidney Disease (CKD) patients suffer from severe metabolic bone disease, which represents a formidable challenge to physicians. Defective vitamin D metabolism, and secondary parathyroid activation have been suggested as possible causes. Vitamin D is important for musculoskeletal health. Vitamin D can be obtained from the diet or made in the skin from exposure to sunlight, but it has to be converted by the kidneys into calcitriol, the active form in order to be effective. Decreased kidney mass in CKD patients causes reduced capability to convert vitamin D into calcitriol due to less 1-alpha hydroxylase enzyme levels. Current standard of care for patients with chronic renal disease is treatment with vitamin D analogues such as Rocaltrol or Hectoral. However, these medications have the potential to cause hypercalcemia. Studies have shown that calcitriol production becoming dependent on 25- hydroxyvitamin D availability in moderate CKD patients. There is speculation that there is still some "reserve" left for the generation of calcitriol from vitamin D in these patients.

The main question being posed in this study is:

Primary: Can a weekly high dose supplementation of cholecalciferol be effective in raising 25(OH)D levels in patients with CKD and can this reduce parathyroid hormone levels in pre-dialysis chronic kidney disease patients?

Study Design This is an 12 week pilot and feasibility study with an enrollment goal of 30 subjects. Half of the subjects will be randomized to vitamin D3 and the other half will receive a placebo. Subjects will be referred from the nutrition or renal clinic at Emory. CKD stage 3 and 4 patients will be eligible for participation if they have been determined to have vitamin D deficiency and are not on treatment with vitamin D or vitamin D analogues. Subjects will sign an informed consent form after reviewing the protocol in detail with the principal investigator. A questionnaire would collect information about dietary vitamin D intake, sunlight exposure, and any symptoms of vitamin D deficiency. The subject will have baseline levels of serum vitamin D (25-hydroxyvitamin D), parathyroid hormone (PTH), serum calcium and phosphate, creatinine and other markers of bone turnover. The questionnaires and the blood draws would be repeated on the 6th and 12th week of the study. Subjects will be given 12 pills of each containing either 50,000 IU vitamin D3 or placebo and asked to take one pill a week. They would be scheduled to return to the clinic after 6 weeks and blood measurements would be repeated. Subjects will be asked to revisit for their final visit at the 12th week when they would have their last blood draw and assessment.

Treatment This is a randomized control trial. Only half of the subjects will receive vitamin D treatment and the other half placebo. If at the end of the study, the subject is still vitamin D deficiency, they will be referred to an endocrinologist or to their primary doctor for treatment.

Scientific advancement If successful, this study would provide the necessary preliminary data in order to conduct a larger randomized controlled study supplementing vitamin D in chronic kidney disease patients. One potential area of study would be to see whether subjects supplemented with vitamin D were able to raise their active vitamin D levels using the "reserve" hydroxylase enzyme in the kidneys compared to those subjects who were just supplemented with a placebo. This study is necessary in order to determine whether weekly intake of a high dose vitamin D is sufficient to decrease the parathyroid hormone levels in the given time frame.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease Vitamin D Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

identical placebo pill orally by mouth

Cholecalciferol

D3

Group Type ACTIVE_COMPARATOR

Cholecalciferol

Intervention Type DRUG

50,000 IU weekly by mouth

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cholecalciferol

50,000 IU weekly by mouth

Intervention Type DRUG

Placebo

identical placebo pill orally by mouth

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vitamin D3 is cholecalciferol D3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-85
* CKD stage 3-4 (GFR 15-59 ml/min/1.73 m2 body surface area, calculated by using the MDRD Study equation GFR Calculator)
* serum 25(OH)D concentrations ≤ 30 ng/mL, and serum PTH levels \>70 pg/mL documented within the last six months

Exclusion Criteria

* History of liver failure (serum AST or ALT \> 3-fold the upper limit of normal)
* requiring dialysis at any stage of the study
* history of intestinal malabsorption or chronic diarrhea
* serum calcium level (corrected for serum albumin) \> 10.5 mg/dL
* calcium x phosphorus product \>70
* treatment with more than 1000 IU of vitamin D per day, or current treatment with a vitamin D analogue or calcimimetic
* an anti-epileptic medication and other medications which can affect vitamin D metabolism (e.g., phenobarbital, phenytoin, rifampicin)

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No